Three key messages on tuberculosis control
Three key messages on tuberculosis control. World Tuberculosis Day 2010. ECDC TB Team European Centre for Disease Prevention and Control Stockholm, 24 March 2010. Message 1 The treatment success rate in the EU/EEA is too low to meet global targets.
Three key messages on tuberculosis control
E N D
Presentation Transcript
Three key messages on tuberculosis control World Tuberculosis Day 2010 ECDC TB TeamEuropean Centre for Disease Prevention and Control Stockholm, 24 March 2010
Message 1 The treatment success rate in the EU/EEA is too low to meet global targets
1a. The treatment success rate in the EU/EEA is too low to meet global targets • Reported treatment success rates in the EU/EEA are far below the 85% target set by the WHO World Health Assembly. Only three EU/EEA countries recorded a treatment success rate over 85% or more for new laboratory-confirmed pulmonary TB cases. Figure 1a: Treatment success rate among new laboratory-confirmed pulmonary TB cases, 2007 85% target set by the Stop TB Partnership. Only Iceland, Portugal and Slovakia meet the 85% target. * Treatment success rate among not previously diagnosed cases. Source: ECDC
1b. The treatment success rate in the EU/EEA is too low to meet global targets Figure 1b: Percentage success rate among laboratory-confirmed new pulmonary TB cases, EU/EEA, 2007 < 60% 60 to 70% 71 to 84% ≥ 85% Not included or not reporting • Source: ECDC
1c. The treatment success rate in the EU/EEA is too low to meet global targets • Treatment success among previously untreated laboratory-confirmed pulmonary TB remains low in the EU/EEA and is below the 85% target. No changes in the trend were seen in the last five years. • Figure 1c: EU/EEA treatment outcome among laboratory-confirmed pulmonary cases 2003–2007 Transferred or unknown Still on treatment 100 90 80 70 60 50 40 30 20 10 0 Defaulted Failed Died Success • * Excluded: Austria, Bulgaria, Cyprus, Finland, France, Greece, Italy, Liechtenstein and Spain
Message 2 Multidrug-resistant tuberculosis (MDR TB) remains a problem in the EU/EEA
Figure 2a: Proportion of notified TB cases with primary multidrug resistance, EU/EEA, 2008 2a. MDR TB* remains a problem in the EU/EEA < 1% 1 to 1.9% 2 to 5.9% > 6-10% > 10% Not included or not reporting * Multidrug-resistant tuberculosis (MDR TB) is defined as TB that is resistant at least to isoniazid (INH) and rifampicin (RMP), the two most powerful first-line anti-TB drugs.
90 78% 80 70 60 50 40 31% 30 17% 17% 17% 20 13% 7% 10 6% 5% 5% 3% 2% 0 MDR MDR MDR MDR MDR MDR Success Died Failed Defaulted Still on treatment Transferred or unknown 2b. MDR TB remains a problem in the EU/EEA • Treatment success rate among MDR TB cases is extremely low (31%). • Figure 2b: Treatment outcome of all* MDR TB cases, compared to all non-MDR cases, EU/EEA, 2006** Non-MDR Non-MDR Non-MDR Non-MDR Non-MDR Non-MDR * Pulmonary and extra-pulmonary ** Both groups are 2006 treatment cohorts
Message 3 The decline in tuberculosis has levelled off in the EU/EEA
3a. The decline in tuberculosis has levelled off in the EU/EEA • The decrease in TB notification rates has stagnated in the EU/EEA. • The decline seen in countries with high and intermediate incidence rates contributes substantially to the average EU/EEA decline. • Figure 3a:TB notification rates by incidence grouping, 1995–2008 and 2002–2008 >20/100 000 Notification rate (per 100 000 population) EU/EEA <20/100 000 • Source: ECDC
3b. The decline in tuberculosis has levelled off in the EU/EEA • Figure 3b:TB notification rates, 1995–2008, EU/EEA 2000 2002 2004 2006 2008 25 20 15 10 5 0 2001 2003 2005 2007 1995 1997 1999 1996 1998 Notification rate (per 100 000 population)